enGene Therapeutics (ENGN) Interest Expenses (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Interest Expenses of $10.9 million for Q2 2026, up 142.9% year-over-year from $4.5 million in Q2 2025, and up 1384.29% quarter-over-quarter from $732000.0 in Q1 2026.
enGene Therapeutics (ENGN) Interest Expenses (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Interest Expenses for 5 consecutive years, with $10.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses rose 142.9% year-over-year to $10.9 million; the TTM figure through Apr 2026 stood at $10.9 million (up 142.9% YoY), while the FY2025 annual figure was $11.0 million, down 77.59% from the prior year.
- Interest Expenses rose to $10.9 million in Q2 2026 per ENGN's latest filing, from $732000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $41.2 million in Q2 2024 and bottomed at -$2000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $5.9 million across 5 years, with a median of $1.2 million in 2023.
- Annual changes were most pronounced in 2023 — Interest Expenses tumbled 101.0% — and 2024, when it soared 8000.0%.
- enGene Therapeutics' Interest Expenses stood at $200000.0 in 2022, then slumped by 101.0% to -$2000.0 in 2023, then jumped by 8000.0% to $158000.0 in 2024, then surged by 796.2% to $1.4 million in 2025, then soared by 667.3% to $10.9 million in 2026.
- Business Quant data shows ENGN's Interest Expenses at $10.9 million in Q2 2026, $732000.0 in Q1 2026, and $1.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 93.62 Mn |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - | 745,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 10.87 Mn |
| Apr 30, 2026 | 10.87 Mn |
| Jan 31, 2026 | 732,000.00 |
| Jan 31, 2026 | 732,000.00 |
| Oct 31, 2025 | 1.42 Mn |
| Oct 31, 2025 | 1.42 Mn |
| Jul 31, 2025 | 4.13 Mn |
| Jul 31, 2025 | 4.13 Mn |
| Apr 30, 2025 | 4.47 Mn |
| Apr 30, 2025 | 4.47 Mn |
| Jan 31, 2025 | 800,000.00 |
| Jan 31, 2025 | 800,000.00 |
| Oct 31, 2024 | 158,000.00 |
| Oct 31, 2024 | 158,000.00 |
| Jul 31, 2024 | 20.72 Mn |
| Jul 31, 2024 | 20.72 Mn |
| Apr 30, 2024 | 41.18 Mn |
| Apr 30, 2024 | 41.18 Mn |
| Jan 31, 2024 | 600,000.00 |
| Jan 31, 2024 | 600,000.00 |